In summary, we have established four predicting models for four kinds of immunohistochemical biomarkers (Ki-67, S-100, vimentin and CD34) in gliomas patients based on T2 FLAIR radiomics, which are potential for imaging-based prediction of tumor proliferation, malignancy, therapeutic effectiveness, migratory or invasion, and angiogenesis. Here, S100A1 is linked to glioma.